

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7833485

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
MICHAEL D. KAUFMAN	02/06/2021
RECEIVING PARTY DATA	
Name:	DECIPHERA PHARMACEUTICALS, LLC
Street Address:	200 SMITH STREET
City:	WALTHAM
State/Country:	MASSACHUSETTS
Postal Code:	02451
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	18148766
CORRESPONDENCE DATA	
Fax Number:	(617)523-1231
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(617) 305-8070
Email:	us-patentbos@goodwinlaw.com, ABeaulieu@goodwinlaw.com
Correspondent Name:	GOODWIN PROCTER LLP
Address Line 1:	100 NORTHERN AVENUE
Address Line 2:	IP DOCKETING DEPT./7TH FL
Address Line 4:	BOSTON, MASSACHUSETTS 02210
ATTORNEY DOCKET NUMBER:	DCP-090C3
NAME OF SUBMITTER:	GREGORY D. GUTIERREZ
SIGNATURE:	/Gregory D. Gutierrez/
DATE SIGNED:	03/08/2023
Total Attachments: 3	
source=DCP-090C1 - DCP_090WO_001 Assignment Kaufman 2021-1#page1.tif	
source=DCP-090C1 - DCP_090WO_001 Assignment Kaufman 2021-1#page2.tif	
source=DCP-090C1 - DCP_090WO_001 Assignment Kaufman 2021-1#page3.tif	

ASSIGNMENT

For good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, I, the undersigned

Michael D. Kaufman of 200 Smith Street, Waltham, Massachusetts 02451, USA, hereby:

Sell, assign and transfer to **Deciphera Pharmaceuticals, LLC**, a Limited Liability Company organized under and pursuant to the laws of Delaware, having a place of business at **200 Smith Street, Waltham, Massachusetts 02451**, its successors, assigns and legal representatives, all hereinafter referred to as said Assignee, the entire right, title and interest for the United States and all foreign countries, in and to any and all inventions which are disclosed in the International Application for Patent filed with the United States Patent and Trademark Office as Receiving Office of the World Intellectual Property Organization in accordance with the Patent Cooperation Treaty (PCT) on:

December 30, 2020

under Application Serial No. PCT/US2020/067560 and

Entitled **COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA**,

and in and to said application and all continuing, divisional, continuation-in-part, substitute, renewal, reissue and all other applications for Letters Patent which have been or shall be filed in the United States and all foreign countries on said any and all inventions; and in and to all original and reissued patents which have been or shall be issued in the United States and all foreign countries on said any and all inventions including the right to apply for patent rights in each foreign country and all rights to priority; and further including any right to sue for past infringement;

Agree that said Assignee may apply for and receive Letters Patent for said any and all inventions in its own name; and when requested, without charge to but at the expense of said Assignee, We agree to carry out in good faith the intent and purpose of this assignment, by executing all divisional, continuing, substitute, renewal, reissue, and all other patent applications on said any and all inventions, by executing all rightful oaths, assignments, powers of attorney and other papers, by communicating to said Assignee all facts known to relating to said any and all inventions and the history thereof, and generally by doing everything reasonably possible which said Assignee shall consider desirable for aiding in securing and maintaining proper patent protection for said any and all inventions and for vesting title to said any and all inventions and all applications for patents and all patents on said inventions, in said Assignee;

Request the Honorable Commissioner of Patents and Trademarks to issue said Letters Patent to said Assignee; and

Covenant with said Assignee that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been made to others by me and that full right to convey the same as herein expressed is possessed by me.

Said Assignee does hereby acknowledge and accept the above sale, assignment and transfer of all the rights, title and interest enumerated above, including but not limited to the right to priority and the right to sue for past infringement.

In the event that the execution date, filing date and/or Application No. are not entered or are incorrect at the time Assignor(s) executed this document, Assignor(s) hereby authorize and request an attorney of Assignee to insert the information or make the correction.


By: **DECIPHERA PHARMACEUTICALS, LLC**

06 Feb 2021
Date


Signature

Michael D. Kaufman
Printed Name of Signor

Vice President, Chemical & Pharmaceutical Development
Title/Authority of Signor




Michael D. Kaufman

Date: 06 Feb 2021

United States of America)
State of Kansas) ss.:
County of Woods)

On this 6th day of February, 2021, before me personally came Michael D. Kaufman, to me known to be the individual described in and who executed the foregoing instrument, and acknowledged execution of the same.


Notary Public